secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004558
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics: $850.7M cash, pipeline progress, 2025 catalysts detailed
---------------------------------------------------------------------------

- Preliminary cash, equivalents and marketable securities of $850.7M as of Dec 31, 2024; runway now into 2027 including BEAM-101 commercial readiness.
- More than 40 adult SCD patients enrolled in BEACON trial; Beam expects to dose 30 patients and present updated data by mid-2025.
- Initial Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency expected in first half 2025.
- BEAM-301 Phase 1/2 trial in GSD1a: first site active, dosing to commence in early 2025.
- ESCAPE nongenotoxic conditioning IND-enabling studies underway; BEAM-103 healthy volunteer study expected by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025004558/0000950170-25-004558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025004558/beam-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer